2 news items
CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24
CRVO
15 Apr 24
phosphorylation and supports the inhibition of p38 MAPK as a promising therapeutic strategy in tauopathies.
Integrated Summary of Phase
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
ASPI
AYTU
BIXT
2 Apr 24
teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth
- Prev
- 1
- Next